Intrahepatic cholangiocarcinoma, although relatively rare, presents formidable treatment challenges due to its aggressive nature and typically late presentation. Surgical resection remains the cornerstone of curative intent therapy, yet the high recurrence rate and modest survival outcomes after surgery alone prompt the oncology community to explore adjunctive treatment avenues. Neoadjuvant chemotherapy (NAT)—which involves administering chemotherapy before surgery—is hypothesized to downstage tumors, reduce micrometastatic disease, and potentially improve the rates of complete tumor removal (R0 resection), thereby augmenting long-term survival.

The meta-analysis methodically aggregated data from nine retrospective studies encompassing a remarkable cohort of 8,211 patients, dividing them into two groups: 1,836 patients who received NAT followed by surgical resection, and 6,375 who underwent upfront surgery without prior chemotherapy. The inclusion of multiple large-scale studies and comprehensive patient data bolsters the statistical power and reliability of the findings. Notably, the study employed the ROBINS-I tool to critically appraise the methodological quality of non-randomized interventions, ensuring robust analytical rigor.

One of the most compelling revelations of the study lies in the overall survival (OS) analyses at multiple time points. Patients receiving NAT followed by surgery exhibited significantly enhanced 1-year and 3-year OS rates compared to their counterparts undergoing immediate surgery. Specifically, the relative risk (RR) improvements were quantified at 1.09 for 1-year OS and 1.15 for 3-year OS, indicating a meaningful survival advantage imparted by preoperative chemotherapy. These findings illuminate the potential of NAT to improve early and mid-term survival trajectories in ICC treatment.

Intriguingly, although the 5-year OS benefit for the NAT group showed a relative risk of 1.16, statistical significance was not definitively achieved, suggesting that longer-term survival may be influenced by a confluence of factors beyond initial treatment modality. This nuance underscores the complexity of ICC progression and the multifaceted interplay between tumor biology, systemic therapy response, and surgical outcomes. It also signals a critical need for further prospective studies focusing on optimizing late-stage survival.

Recurrence-free survival (RFS), a vital metric indicating the duration patients remain free from cancer relapse post-treatment, was similar between both groups at 1-year and 3-year intervals. This equivalence in RFS outcomes suggests that while NAT may confer an early survival benefit, it does not necessarily translate into a sustained decrease in recurrence rates within the studied follow-up window. These data challenge assumptions about the role of chemotherapy in altering tumor recurrence dynamics and elicit important questions about disease biology.

The rate of R0 resection—defined as complete surgical excision of the tumor with no microscopic residual disease at margins—was also found to be statistically analogous between the groups. This outcome is particularly striking because NAT is often posited to increase resectability by shrinking tumors preoperatively. The lack of a differential in R0 rates may reflect the complexity of ICC tumor spread patterns or indicate that patient selection criteria significantly influence surgical success, regardless of neoadjuvant treatment.

Another compelling aspect of this meta-analysis is the recognition that patients receiving NAT generally presented with more advanced disease compared to the upfront surgery cohort. Despite this prognostic disadvantage, the NAT group achieved similar or superior survival outcomes, lending credence to the therapeutic value of chemotherapy in managing locally advanced ICC. This observation may redefine treatment stratification paradigms, suggesting a rationale for adopting neoadjuvant approaches even in patients with more aggressive tumor characteristics.

The biological rationale underpinning neoadjuvant chemotherapy effectiveness involves its systemic action against both primary tumor cells and occult metastatic disease. This dual mechanism theoretically mitigates micrometastatic spread that surgery alone cannot address. Furthermore, early systemic treatment may induce tumor regression, easing surgical resection and potentially improving postoperative recovery and outcomes. However, the differential impacts on tumor microenvironment, chemotherapy resistance mechanisms, and patient-specific pharmacodynamics remain areas ripe for future investigation.

While retrospective data offer invaluable insights, inherent limitations such as selection bias and confounding variables temper the conclusiveness of findings. The authors of this meta-analysis rightfully call for prospective, randomized controlled trials to validate these results and optimize chemotherapeutic regimens, timing, and combinations tailored for ICC. Elucidating molecular predictors of response to NAT could further refine patient selection, maximizing therapeutic benefit while minimizing unnecessary treatment-associated morbidity.

Emerging therapeutic frontiers, including targeted therapies and immunotherapies combined with neoadjuvant chemotherapy, hold promise for enhancing treatment efficacy. The integration of genomic profiling and personalized medicine approaches may revolutionize ICC management in the coming years. Furthermore, development of reliable biomarkers to monitor treatment response dynamically during NAT could enable timely adaptations to therapeutic strategies, fostering precision oncology.

This meta-analysis also underscores the critical need to develop effective downstaging treatments, especially for locally advanced ICC where curative resection is challenging. Optimizing neoadjuvant protocols could improve operability and mitigate recurrence risk, ultimately enhancing long-term survival. Multidisciplinary collaborations involving oncologists, hepatobiliary surgeons, radiologists, and pathologists are essential to advance integrated treatment pathways and refine clinical decision-making in ICC care.

A pragmatic implication of these findings is the potential shift in clinical guidelines for intrahepatic cholangiocarcinoma. As evidence accrues favoring NAT followed by surgery, oncological practice may evolve toward routinely incorporating systemic therapy before resection in appropriate candidates. This paradigm shift could reshape patient counseling, surgical planning, and healthcare resource allocation, aiming for improved survival outcomes and quality of life.

Considering the global burden of liver cancers and the rising incidence of ICC, timely advances in treatment strategies carry significant public health importance. The synthesis of multicenter data in this meta-analysis contributes a critical foundation for evidence-based practice evolution. Continued investment in translational research and clinical trials is indispensable to close existing knowledge gaps and advance therapeutic efficacy.

In conclusion, this systematic review and meta-analysis provide compelling evidence that neoadjuvant chemotherapy followed by surgery yields superior 1-year and 3-year overall survival for patients with resectable and locally advanced intrahepatic cholangiocarcinoma. Despite comparable recurrence-free survival and R0 resection rates, the findings suggest a survival advantage that may justify incorporating NAT into standard treatment paradigms. The research sets the stage for future investigations aimed at optimizing downstaging protocols and personalizing treatment to transform ICC prognosis fundamentally.

Subject of Research:
Comparative efficacy of neoadjuvant chemotherapy followed by surgery versus upfront surgery in the treatment of intrahepatic cholangiocarcinoma.

Article Title:
Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis

Article References:
Liu, Y., Wu, C., Huang, Q. et al. Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. BMC Cancer 25, 1757 (2025). https://doi.org/10.1186/s12885-025-15203-8

Image Credits:
Scienmag.com

DOI:
https://doi.org/10.1186/s12885-025-15203-8

Hepatic malignancies often present unique hurdles due to the liver’s complex vascular and biliary architecture. In iCCA, the presence of multiple lesions within one hepatic lobe adds layers of diagnostic and therapeutic complexity. While solitary tumors have traditionally been the primary candidates for curative surgical intervention, the treatment paradigm for multifocal tumors is far less defined. This new investigation categorized multifocal tumors based on lesion count and localization, stratifying them into three types: solitary tumors (Type I), two or three lesions confined to the same hepatic lobe (Type II), and cases with more than three lesions in the same lobe (Type III).

The researchers conducted a comprehensive retrospective analysis of 354 consecutive patients diagnosed with iCCA who underwent radical surgical resection. By incorporating stabilized inverse probability treatment weighting (IPTW), a statistical method used to reduce confounding factors in observational studies, they achieved an unbiased comparison of survival outcomes across the different lesion-number groups. This methodological rigor strengthens the study’s reliability and offers compelling evidence guiding surgical decisions in multifocal iCCA.

One of the striking findings was the stark contrast in overall survival (OS) and recurrence-free survival (RFS) between solitary and multifocal tumors. Patients with multifocal iCCA had significantly worse survival outcomes compared to those with solitary tumors, underscoring the aggressive nature of multifocal disease. However, within the multifocal cohort, survival varied considerably depending on lesion number. Those with two or three lesions exhibited survival rates comparable to solitary tumors after adjustment for baseline differences, whereas patients with more than three tumors experienced markedly worse prognoses.

Delving into the pathological dynamics influencing these outcomes reveals the biological aggressiveness associated with higher tumor burden. Multivariable Cox proportional hazards modeling confirmed that having more than three hepatic lesions is an independent risk factor for decreased overall survival, nearly doubling the hazard ratio compared to solitary tumors. This quantification highlights the intrinsic relationship between tumor multiplicity and tumor biology, possibly reflecting greater intraparenchymal spread, increased metastatic potential, or resistance to therapeutic interventions.

The study also situated its findings within the widely used American Joint Committee on Cancer (AJCC) staging framework, focusing particularly on stage II (T2N0M0) patients characterized by vascular invasion. It emerged that in this subgroup, multifocal tumors of type III had significantly worse overall survival than solitary tumors, while type II multifocal tumors showed survival rates akin to solitary lesions. This nuance indicates that not all multifocal iCCA cases should be treated homogeneously; instead, the number of lesions might refine the staging impact and subsequently influence treatment strategies.

Moreover, when comparing stage II and stage III patients, a paradoxical pattern emerged. Type II multifocal tumors demonstrated better survival than stage III patients, whereas type III tumors had similar survival, suggesting that lesion count could potentially supersede traditional staging in predicting outcomes. This could redefine risk stratification approaches and pave the way for more personalized surgical planning.

The implications of these findings resonate profoundly in the clinical decision-making process. Radical surgery, currently advocated as the cornerstone treatment for solitary iCCA, may also be justifiable and beneficial for patients classified as type II multifocal tumors. This challenges previous reticence around aggressive surgery in multifocal settings and advocates for a more nuanced patient selection, balancing the extent of surgical intervention with anticipated survival benefits.

Conversely, the dismal prognosis observed in patients with more than three hepatic lesions underscores the necessity of adjunct or alternative therapeutic modalities. For this subset, multimodal approaches including systemic chemotherapy, locoregional therapies, or inclusion in clinical trials might be warranted to improve outcomes. The study thus not only informs surgical candidacy but also signals an urgent unmet clinical need in managing extensive multifocal disease.

Beyond immediate clinical implications, this research invites further exploration into the molecular and genetic underpinnings differentiating multifocal iCCA subtypes. An improved understanding of the tumor microenvironment, genetic mutations contributing to multifocality, and mechanisms driving aggressive phenotypes could catalyze the development of targeted therapies, complementing surgical treatment.

From an epidemiological perspective, the study’s large, well-characterized cohort provides robust data for future meta-analyses and baseline comparisons. By standardizing the classification of multifocal tumors according to lesion number and location, it facilitates cross-study comparability and optimizes collaborative research efforts.

Furthermore, employing IPTW propensity-score analysis sets a methodological precedent in hepatobiliary oncology. This approach mitigates selection biases inherent in retrospective studies, thereby enhancing the validity of survival comparisons and offering a replicable model for similar investigations in complex oncologic scenarios.

In summary, this pioneering work decisively establishes that the number of hepatic lesions in multifocal intrahepatic cholangiocarcinoma is a critical prognostic determinant following radical resection. While multifocal iCCA overall portends a poorer prognosis compared to solitary tumors, patients bearing two or three lesions in the same hepatic lobe appear to obtain comparable oncological benefits from surgery. These insights advocate for the inclusion of lesion count in staging systems and treatment algorithms, promoting more personalized and effective management strategies.

This research uncovers a transformative avenue in the surgical oncology of iCCA, challenging entrenched perceptions and potentially expanding surgical indications. By reconciling tumor burden with survival outcomes, it equips clinicians with data-driven frameworks essential for optimizing patient-centric care in a notoriously lethal malignancy.

As the liver oncology field advances, integrating these findings with emerging systemic therapies and precision medicine approaches will be crucial. Ultimately, refining prognostic models based on lesion count and biological characteristics holds promise for enhancing survival and quality of life in patients afflicted with multifocal intrahepatic cholangiocarcinoma.

Subject of Research: Prognostic impact of hepatic lesion number in multifocal intrahepatic cholangiocarcinoma after radical surgery.

Article Title: Prognostic significance of the number of hepatic lesions in multifocal intrahepatic cholangiocarcinoma after radical resection: an IPTW propensity-score analysis.

Article References:
Zhang, X., Huang, XT., Xie, JZ. et al. Prognostic significance of the number of hepatic lesions in multifocal intrahepatic cholangiocarcinoma after radical resection: an IPTW propensity-score analysis. BMC Cancer 25, 930 (2025). https://doi.org/10.1186/s12885-025-13737-5

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-13737-5